Aclaris says FDA grants Fast Track status for modzatinib in moderate to severe lichen planus

Reuters2026/08/06 22:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Aclaris Therapeutics received FDA Fast Track designation for modzatinib (ATI-2138) in moderate to severe lichen planus.
The designation supports an expedited development and review path, including potential rolling NDA submission.
A phased, multi-part Phase 2b trial is expected to start in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Aclaris says FDA grants Fast Track status for modzatinib in moderate to severe lichen planus

You may also like

Crypto prices